

New Products - Erivedge

Erivedge (**vismodegib**) is a low molecular weight, orally available inhibitor of the Hedgehog pathway. The Hedgehog pathway signalling through the smoothed transmembrane protein (SMO) leads to the activation and nuclear localisation of GLI transcription factors and induction of Hedgehog target genes. Vismodegib binds to and inhibits SMO, thereby preventing Hedgehog signal transduction. Erivedge is indicated for the treatment of adult patients with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma where surgery and/or radiation therapy are not appropriate. Erivedge is contraindicated in pregnancy; women of childbearing potential, unless two reliable methods of contraception are being used during treatment and for 7 months after the last dose. It is also contraindicated in nursing mothers during the course of treatment and for 7 months after the last dose because of the potential to cause serious development defects in breastfed infants and children. Erivedge is available as a 150 mg tablet in packs of 28's.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.